FLT3 and acute myeloid leukemia: Despite comparable use of induction chemotherapy and complete remission rates between FLT3-ITD and wild-type FLT3 AML patients, the significantly shorter overall survival in the FLT3-ITD group highlights the dismal prognosis associated with this mutation.